Who is running the study?

EASi-KIDNEY^TM will be coordinated by scientists from Oxford Population Health’s Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU), part of the University of Oxford. CTSU is one of the world’s leading centres for this type of research. More details of our team are available on our website: www.ctsu.ox.ac.uk/research/renal-studies-group. The Oxford team will be supported by many kidney doctors and other specialty doctors and nurses around the world, to make this ‘megatrial’ possible.

The EASi-KIDNEY^TM team has permission from the relevant ethics committee to do the study (Oxfordshire Research Ethics Committee B, Ref No. 24/SC/0147). This committee has checked that the health question being asked is important enough to warrant a study, and that the study is being carried out in an independent, honest, and professional manner.

An independent committee of experts also watches over the study and keeps an eye on the safety of the participants. This committee could stop the study early if there was important new information from this, or other, studies which affected whether EASi-KIDNEY^TM should continue.

If the study is stopped, the reason(s) for this and what the next steps are (including any adjustments to your management) will be explained by your study team following discussion with your local doctor.

Studies such as EASi-KIDNEY^TM take a very large amount of collaborative effort from many hundreds of research staff around the world and can be costly to run. The study is sponsored by Boehringer Ingelheim, which is also providing the study pills and a grant to the University of Oxford. Those running the study at the University of Oxford have also received support from the Medical Research Council and British Heart Foundation to run trials.